{"id":39090,"date":"2025-01-27T20:33:06","date_gmt":"2025-01-27T17:33:06","guid":{"rendered":"https:\/\/entarabi.com\/?p=39090"},"modified":"2025-01-27T21:23:23","modified_gmt":"2025-01-27T18:23:23","slug":"biosapien-expands-its-pre-series-a-round-to-7-million-to-advance-the-medichip-platform","status":"publish","type":"post","link":"https:\/\/entarabi.com\/en\/2025\/01\/biosapien-expands-its-pre-series-a-round-to-7-million-to-advance-the-medichip-platform\/","title":{"rendered":"Biosapien Expands Its Pre-Series A Round to $7 Million to Advance the MediChip Platform"},"content":{"rendered":"<ul>\n<li dir=\"ltr\" style=\"text-align: left;\">Biosapien has announced the expansion of its Pre-Series A funding round to $7 million to support the development of its groundbreaking <strong>MediChip<\/strong> platform.<\/li>\n<li dir=\"ltr\" style=\"text-align: left;\">The company plans to launch clinical trials in the UAE by <strong>Q2 2025<\/strong>, focusing on treatments for <strong>colorectal cancer<\/strong>.<\/li>\n<li dir=\"ltr\" style=\"text-align: left;\"><strong>MediChip<\/strong> leverages 3D printing technology to revolutionize drug delivery by providing targeted, slow-release medication. The technology aims to treat <strong>over 1 million patients<\/strong> by 2035, offering innovative solutions that enhance treatment efficiency and minimize side effects.<\/li>\n<\/ul>\n<p dir=\"ltr\"><strong>Dubai, UAE<\/strong> \u2013 Biosapien, a leading biotech company, has announced the expansion of its Pre-Series A funding round to $7 million. This milestone was achieved with the participation of new investors, including <strong>Golden Gate Ventures<\/strong>, marking its first investment in the Middle East and North Africa (MENA) region.<\/p>\n<p dir=\"ltr\">This funding builds on a previous $5.5 million round announced last December, led by <strong>Global Ventures<\/strong> with the participation of <strong>Dara Holdings<\/strong>.<\/p>\n<h3 dir=\"ltr\">Driving Innovation with the MediChip Platform<\/h3>\n<p dir=\"ltr\">MediChip is a groundbreaking drug delivery system developed using 3D printing technology. It features slow drug-release capabilities and can be directly attached to affected tissues, reducing the required dosage while enhancing treatment efficacy and minimizing side effects.<\/p>\n<h4 dir=\"ltr\">Key Advantages of MediChip Technology:<\/h4>\n<ul dir=\"ltr\">\n<li><strong>Direct Tumor Targeting<\/strong>: Focuses treatment on the tumor site.<\/li>\n<li><strong>Reduced Drug Quantities<\/strong>: Minimizes medication usage.<\/li>\n<li><strong>Fewer Systemic Side Effects<\/strong>: Enhances patient comfort and outcomes.<\/li>\n<\/ul>\n<p dir=\"ltr\">Biosapien plans to launch clinical trials targeting <strong>colorectal cancer patients<\/strong> in the UAE by Q2 2025. Future plans include extending the technology\u2019s application to other cancers, such as <strong>pancreatic<\/strong> and <strong>lung cancer<\/strong>.<\/p>\n<h3 dir=\"ltr\">Broader Applications Beyond Cancer<\/h3>\n<p dir=\"ltr\">MediChip\u2019s versatility extends beyond oncology to include:<\/p>\n<ul dir=\"ltr\">\n<li><strong>Chronic Diseases<\/strong>: Leveraging opioids and hormones.<\/li>\n<li><strong>Advanced Therapies<\/strong>: Supporting biological, cellular, and genetic treatments.<\/li>\n<\/ul>\n<p dir=\"ltr\">Biosapien aims to treat over <strong>1 million patients<\/strong> by 2035, aligning with the UAE\u2019s commitment to advanced healthcare initiatives and improving quality of life through cutting-edge technologies.<\/p>\n<p dir=\"ltr\">This expansion underscores Biosapien\u2019s vision to redefine drug delivery and revolutionize patient care on a global scale.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biosapien has announced the expansion of its Pre-Series A funding round to $7 million to support the development of its groundbreaking MediChip platform. The company plans to launch clinical trials in the UAE by Q2 2025, focusing on treatments for colorectal cancer. MediChip leverages 3D printing technology to revolutionize drug delivery by providing targeted, slow-release [&hellip;]<\/p>\n","protected":false},"author":37,"featured_media":37571,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"post_subtitle":"","footnotes":""},"categories":[1810],"tags":[6439,6832,2821,6831],"class_list":["post-39090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fintech","tag-biosapien","tag-dara-holdings-en","tag-global-ventures-2","tag-medichip-en"],"_links":{"self":[{"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/posts\/39090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/users\/37"}],"replies":[{"embeddable":true,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/comments?post=39090"}],"version-history":[{"count":0,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/posts\/39090\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/media\/37571"}],"wp:attachment":[{"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/media?parent=39090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/categories?post=39090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/entarabi.com\/en\/wp-json\/wp\/v2\/tags?post=39090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}